Randomized controlled feasibility trial of supported self-management in adults with Type 2 diabetes mellitus and an intellectual disability: OK Diabetes
dc.contributor.author | House, A | |
dc.contributor.author | Bryant, L | |
dc.contributor.author | Russell, AM | |
dc.contributor.author | Wright-Hughes, A | |
dc.contributor.author | Graham, L | |
dc.contributor.author | Walwyn, R | |
dc.contributor.author | Wright, JM | |
dc.contributor.author | Hulme, C | |
dc.contributor.author | O'Dwyer, JL | |
dc.contributor.author | Latchford, G | |
dc.contributor.author | Stansfield, A | |
dc.contributor.author | Ajjan, R | |
dc.contributor.author | Farrin, A | |
dc.date.accessioned | 2022-07-21T10:54:55Z | |
dc.date.issued | 2018-03-25 | |
dc.date.updated | 2022-07-21T10:14:31Z | |
dc.description.abstract | AIMS: To undertake a feasibility randomized controlled trial of supported self-management vs treatment as usual in a population of adults with obesity, Type 2 diabetes and an intellectual disability. METHODS: We conducted an individually randomized feasibility trial. Participants were adults aged >18 years with a mild or moderate intellectual disability, living in the community with Type 2 diabetes, on any therapy other than insulin. Participants had mental capacity to consent to research and the intervention. Inclusion criteria included HbA1c > 48 mmol/mol (6.5%), BMI >25 kg/m2 , or self-reported physical activity below national guideline levels. The experimental intervention was standardized supported self-management delivered by diabetes specialist nurses plus treatment as usual, compared with treatment as usual alone. Feasibility outcomes included: recruitment and retention; intervention acceptability and feasibility; data collection and completeness for physiological state and values for candidate primary outcomes (HbA1c and BMI). RESULTS: A total of 82 participants (89% of those contacted and eligible) were randomized. All supported self-management sessions were completed by 35/41 participants (85%); only four completed no sessions. Data on the follow-up candidate primary outcomes HbA1c and BMI were obtained for 75/82 (91%) and 77/82 participants (94%), respectively. The mean baseline HbA1c was 56±16.5 mmol/mol (7.3±1.5%) and the mean BMI was 34±7.6 kg/m2 . CONCLUSIONS: Adherence to supported self-management and willingness to have blood taken for outcome measurement was good. A definitive randomized controlled trial is feasible in this population. | en_GB |
dc.description.sponsorship | National Institute for Health Research Health Technology Assessment programme | en_GB |
dc.format.extent | 776-788 | |
dc.format.medium | Print-Electronic | |
dc.identifier.citation | Vol. 35 (6), pp. 776-788 | en_GB |
dc.identifier.doi | https://doi.org/10.1111/dme.13626 | |
dc.identifier.grantnumber | 10/102/03 | en_GB |
dc.identifier.uri | http://hdl.handle.net/10871/130321 | |
dc.identifier | ORCID: 0000-0003-2077-0419 (Hulme, C) | |
dc.language.iso | en | en_GB |
dc.publisher | Wiley / Diabetes UK | en_GB |
dc.relation.url | https://www.ncbi.nlm.nih.gov/pubmed/29575241 | en_GB |
dc.rights | © 2018 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. | en_GB |
dc.title | Randomized controlled feasibility trial of supported self-management in adults with Type 2 diabetes mellitus and an intellectual disability: OK Diabetes | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2022-07-21T10:54:55Z | |
dc.identifier.issn | 0742-3071 | |
exeter.place-of-publication | England | |
dc.description | This is the final version. Available from Wiley / Diabetes UK via the DOI in this record. | en_GB |
dc.identifier.eissn | 1464-5491 | |
dc.identifier.journal | Diabetic Medicine | en_GB |
dc.relation.ispartof | Diabet Med, 35(6) | |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | en_GB |
dcterms.dateAccepted | 2018-03-13 | |
dc.rights.license | CC BY-NC | |
rioxxterms.version | VoR | en_GB |
rioxxterms.licenseref.startdate | 2018-03-13 | |
rioxxterms.type | Journal Article/Review | en_GB |
refterms.dateFCD | 2022-07-21T10:47:57Z | |
refterms.versionFCD | VoR | |
refterms.dateFOA | 2022-07-21T10:55:01Z | |
refterms.panel | A | en_GB |
refterms.depositException | publishedGoldOA | |
refterms.dateFirstOnline | 2018-03-25 |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's licence is described as © 2018 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.